Onconetix, INC 8-K filings

Onconetix, Inc. announced a $750 million at-the-market equity offering facility and a $30.25 million private placement of Series F convertible preferred stock.

Onconetix, Inc. is implementing a 1-for-10 reverse stock split to regain compliance with Nasdaq's minimum bid price requirement.

Onconetix, Inc. reports the resignation of two directors and the appointment of Josh Epstein to the Board of Directors.

Onconetix, Inc. announces the appointment of David White as CEO and Sammy Dorf to its Board, alongside a board resignation and compensation adjustments.

Onconetix, Inc. announced the appointment of David White as Chief Executive Officer, the resignation of Timothy Ramdeen from the Board, and the appointment of Sammy Dorf as a new director.

Onconetix, Inc. announced a definitive agreement to acquire Realbotix LLC in an all-stock transaction, marking a strategic shift from biotechnology to AI-powered humanoid robotics.

Onconetix, Inc. stockholders approved a reverse stock split proposal and an adjournment proposal at a special meeting held on February 3, 2026.

Onconetix, Inc. announced the approval of an executive bonus and pay raise, the re-election and election of directors, and the issuance of shares related to recent private placements.

Onconetix's subsidiary, Proteomedix, amended its license agreement with Labcorp to initiate a new validation study for Proclarix, with Onconetix funding up to $300,000.

Onconetix, Inc. announced the date for its 2025 annual meeting of stockholders and established deadlines for shareholder proposals and director nominations.

Onconetix, Inc. announced a $6.25 million private investment in public equity (PIPE) financing through the sale of Series E convertible preferred stock and warrants.

Onconetix, Inc. announced a $12.9 million private placement, settled an $8.8 million debt with Veru Inc., and mutually terminated its merger agreement with Ocuvex Therapeutics, Inc.

Onconetix's subsidiary, Proteomedix, has entered a licensing agreement with Immunovia for key intellectual property related to pancreatic cancer diagnostics.

Onconetix, Inc. announced new promissory notes with Keystone Capital and KCP Fund I, while securing further extensions on its substantial debt obligations to Veru Inc. due to an inability to repay.

Onconetix, Inc. issued a new promissory note for $117,647.06, amended and extended its $5.1 million debt to Veru Inc., and announced a director's resignation.

Onconetix, Inc. has entered into a definitive merger agreement to acquire Ocuvex Therapeutics, Inc., a privately held biopharmaceutical company, with Ocuvex equity holders set to own 90% of the combined entity post-closing.

Onconetix, Inc. announced it received a decision from the Nasdaq Hearings Panel granting its request for continued listing, subject to demonstrating compliance with listing rules by June 30, 2025, following a recent reverse stock split.

Onconetix, Inc. announced a 1-for-85 reverse stock split effective June 13, 2025, aimed at regaining Nasdaq minimum bid price compliance, and disclosed a new $147,058.82 promissory note with Keystone Capital Partners, LLC.

Onconetix, Inc. announced that its stockholders have approved a reverse stock split at a ratio between 1-for-10 and 1-for-150, aimed at increasing its per-share price and maintaining Nasdaq compliance.

Onconetix, Inc. faces further Nasdaq delisting concerns due to delayed financial filings while securing a $294,117.65 promissory note to address immediate financial needs.

Onconetix, Inc. received a delisting notice from Nasdaq for failing to file its annual report and not meeting the minimum bid price requirement.

Onconetix, Inc. is at risk of being delisted from the Nasdaq due to its stock price falling below the required minimum, and has postponed its annual shareholder meeting.

Onconetix, Inc. and Ocuvex Therapeutics, Inc. have signed a non-binding letter of intent for a potential business combination, expanding Onconetix's reach beyond oncology.

Onconetix, Inc. reports the resignation of James Sapirstein as Executive Chairman and the appointment of Karina Fedasz as Interim CEO, effective immediately.

Onconetix's Proclarix test demonstrates strong clinical performance in a Danish cohort, reducing unnecessary biopsies for prostate cancer diagnosis.

Onconetix's Proclarix prostate cancer test data will be presented at the 2025 European Association of Urology Congress.

Onconetix, Inc. announces the resignation of its Interim CEO and CSO, the appointment of James Sapirstein as Executive Chairman, and the addition of Andrew Oakley to its Board of Directors.

Onconetix, Inc. entered into a promissory note agreement with Keystone Capital Partners, LLC for $117,647 to bolster its financial position.

Onconetix, Inc. has received a notice from Nasdaq for failing to maintain a minimum share price of $1.00, triggering a compliance period to avoid delisting.

Onconetix, Inc. has reached a settlement with IQVIA for $150,000, resolving a dispute over terminated service agreements, and its subsidiary, Proteomedix AG, has published a study highlighting the potential clinical benefits of Proclarix in prostate cancer detection.